
ESSENTIALS IN OPHTHALMOLOGY

G.K.KRIEGLSTEIN · R.N.WEINREB Series Editors



Cataract

Surgery




Disorders

Uveitis Vitreo-retinal and Surgery **Immunological**



Medical Retina



Oculoplastics and Orbit



Pediatric Ophthalmology, Neuroophthalmology, Genetics



Cornea and External Eye Disease

Uveitis and Immunological Disorders

PROGRESS III

Edited by U. PLEYER J. V. FORRESTER



Essentials in Ophthalmology

Uveitis and Immunological Disorders

U. Pleyer J.V. Forrester Editors

Essentials in Ophthalmology

G. K. Krieglstein R. N. Weinreb Series Editors Glaucoma

Cataract and Refractive Surgery

Uveitis and Immunological Disorders

Vitreo-retinal Surgery

Medical Retina

Oculoplastics and Orbit

Pediatric Ophthalmology, Neuro-Ophthalmology, Genetics

Cornea and External Eye Disease

Editors Uwe Pleyer John V. Forrester

Uveitis and Immunological Disorders

Progress III

With 30 Figures, Mostly in Colour and 9 Tables



Series Editors

Günter K. Krieglstein, MD

Professor and Chairman Department of Ophthalmology University of Cologne Kerpener Straße 62 50924 Cologne Germany

Robert N. Weinreb, MD

Professor and Director Hamilton Glaucoma Center Department of Ophthalmology University of California at San Diego 9500 Gilman Drive La Jolla, CA 92093-0946 USA

Volume Editors

Uwe Pleyer, MD

Professor of Ophthalmology Universitätsklinikum Berlin Charité Department of Ophthalmology Augustenburger Straße 1 13353 Berlin Germany

John V. Forrester, MD, FRCSE, FRCSG, FRC Ophth

Cockburn Professor and Head of Department
Department of Ophthalmology
Institute of Medical Sciences, Foresterhill
University of Aberdeen
Aberdeen, AB25 2ZD
Scotland
UK

ISBN 978-3-540-69458-8

e-ISBN 978-3-540-69459-5

ISSN 1612-3212

Library of Congress Control Number: 2008932108

© 2009 Springer-Verlag Berlin Heidelberg

This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other way, and storage in data banks. Duplication of this publication or parts thereof is permitted only under the provisions of the German Copyright Law of September 9, 1965, in its current version, and permission for use must always be obtained from Springer-Verlag. Violations are liable for prosecution under the German Copyright Law.

The use of general descriptive names, registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Product liability: The publishers cannot guarantee the accuracy of any information about dosage and application contained in this book. In every individual case the user must check such information by consulting the relevant literature.

Cover Design: WMXDesign GmbH, Heidelberg, Germany

Printed on acid-free paper

9 8 7 6 5 4 3 2 1

springer.com

Foreword

The Essentials in Ophthalmology series represents an unique updating publication on the progress in all subspecialties of ophthalmology.

In a quarterly rhythm, eight issues are published covering clinically relevant achievements in the whole field of ophthalmology. This timely transfer of advancements for the best possible care of our eye patients has proven to be effective. The initial working hypothesis of providing new knowledge immediately following publication in the peer-reviewed journal and not waiting for the textbook appears to be highly workable.

We are now entering the third cycle of the Essentials in Ophthalmology series, having been encour-

aged by readership acceptance of the first two series, each of eight volumes. This is a success that was made possible predominantly by the numerous opinion-leading authors and the outstanding section editors, as well as with the constructive support of the publisher. There are many good reasons to continue andstill improve the dissemination of this didactic and clinically relevant information.

G.K. Krieglstein R.N. Weinreb Series Editors

Preface

Our knowledge and understanding of immune-mediated diseases has increased exponentially over the past few years, especially in the areas of immunopathogenesis and immunotherapeutics. Uveitis is one of the most common potentially blinding disorders, and one that is often underestimated but is now considered a leading cause of severe eye damage, particularly in younger age groups. Over the past few years, immune-mediated mechanisms—both innate and adaptive—have also been implicated in other disorders, such as diabetic retinopathy and macular degeneration.

This third volume of Uveitis and Immunological Disorders in the Essentials in Ophthalmology series provides the ophthalmologist with practical information on current diagnostic and therapeutic aspects of several ocular disorders from the front to the back of the eye. In addition, there are important discussions of the mechanisms underlying these conditions, which incorporate

the most recent research material available. The scope of the chapters ranges from well-recognized immune disorders such as cornea transplantation, uveitis and diabetic retinopathy, to less well recognized but newly emerging immunologically linked diseases, such as macular degeneration. This book covers, in particular, new aspects of HLA-B27-associated anterior uveitis, keratouveitis, and steroid sensitivity in uveitis patients. Further emphasis is placed on the nature of the intraocular inflammation and systemic disorders such as Behçet's vasculitis and multiple sclerosis.

We are grateful to all of the authors that have contributed to this edition of Uveitis and Immunological Disorders. We are sure that this book will find its audience, and we hope that it will serve in the interest of many patients.

Uwe Pleyer
John V. Forrester

Contents

Chapter 1 Histocompatibility Matching in Penetrating Keratoplasty			2.3.3	HLA-B27-Associated		
				Inflammatory Disease	13	
			2.4	Other Genetic Risk Factors		
Daniel Böhringer, Thomas Reinhard			2.5	for Acute Anterior Uveitis	13	
				Current Understanding of		
1.1	Introduction	1		AAU Pathogenesis	13	
1.2	Major Transplantation		2.5.1	Cytokines	14	
	Antigens (HLA)	1	2.5.2	Toll-Like Receptors (TLR)	14	
1.2.1	Typing Methods	2	2.6	Clinical Features of Acute		
1.2.2	Discussion of the Evidence			Anterior Uveitis	15	
	for HLA Matching in Penetrating		2.6.1	HLA-B27 and Clinical Phenotype	15	
	Keratoplasty	2	2.6.2	Ocular Complications	15	
1.2.3	Differential HLA Matching	3	2.7	Clinical Management of AAU	16	
1.3	Minor (H) Transplantation		2.8	Conclusions	16	
	Antigens	3		References	17	
1.3.1	Discussion of Selected H Antigens	4				
1.3.1.1	H-Y	4	Chapt	er 3		
1.3.1.2	HA-3	4	What	Can the Aqueous Humour		
1.3.1.3	ABO	5	Tell U	s About Uveitis?		
1.4	Practical Concerns:		Alasta	ir K.O. Denniston, S. John Curnow		
	Time on the Waiting List	5				
1.4.1	Waiting Time Variability as a Major		3.1	Clinical Examination of the Aqueous Humou	ır	
	Handicap in HLA Matching	5		in Uveitis	19	
1.4.2	Predicting the Time		3.1.1	Introduction	19	
	on the Waiting List	5	3.1.2	Observable Changes During		
1.5	Recommended Clinical Practice	6		Intraocular Inflammation	19	
	References	6	3.1.3	Sampling of Aqueous Humour	20	
			3.2	Identification of Infectious		
Chapte	r 2			Agents in Aqueous Humour	21	
Acute A	Interior Uveitis and HLA-B27:		3.2.1	Intraocular Antibody and PCR	21	
What's New?			3.2.2	Recent Technological Advances	21	
John H. Chang, Peter J. McCluskey,			3.3	Leukocyte Populations		
	Vakefield			in Aqueous Humour	21	
			3.3.1	The Noninflamed Eye	21	
2.1	Introduction	9	3.3.2	Cytocentrifuge Analysis of		
2.2	Epidemiology of Acute Anterior			Leukocyte Populations		
	Uveitis and HLA-B27	10		in Uveitis Aqueous Humour	21	
2.2.1	Global Patterns of HLA-B27+		3.3.3	Flow Cytometric Analysis		
	Acute Anterior Uveitis	10		of Uveitis Aqueous Humour	22	
2.3	HLA-B27 and Disease	10	3.3.4	Antigen Specificity of Aqueous		
2.3.1	New Developments in the			Humour T Cells	23	
	Immunogenetics of HLA-B27	11	3.4	Changes in the Aqueous Humour		
2.3.2	Role of Microbial Triggers in			Microenvironment During		
	Immune-Mediated Inflammation	12		Episodes of Uveitis	23	

3.4.1	Immunological Properties of		Chapter 5				
	Aqueous Humour		Steroid Sensitivity in Uveitis				
3.4.2	Cytokine Profiles of Aqueous			Richard W.J. Lee, Lauren P. Schewitz,			
	Humour	23	Ben J.	E. Raveney, Andrew D. Dick			
3.4.3	IL-10 In Aqueous Humour	24					
3.5	Summary and Future Directions	25	5.1	Introduction	45		
	References	25	5.2	Glucocorticoids as Regulators			
				of the Immune Response	45		
Chapte			5.2.1	Endogenous Glucocorticoids			
	etic Retinopathy an Inflammatory			and the Hypothalamic–Pituitary–			
	? Inflammation as a Stimulus			Adrenal Axis	45		
for Vaso	cular Leakage and Proliferation		5.2.2	Glucocorticoid Control			
Antonia	M. Joussen			of Cell Function			
				485.2.3 The Interleukin-2/Glucocorticoid			
4.1	Introduction	29		Balance	48		
4.1.1	Clinical Problems and Cellular		5.3	Glucocorticoids in the Treatment			
	Interaction in Diabetic			of Noninfectious Uveitis	48		
	Retinopathy	29	5.4	Steroid Sensitivity in Other			
4.1.2	Elevated Adhesion Molecules			Inflammatory Diseases	49		
	and Inflammatory Mediators		5.4.1	The Concept of a Common			
	in Diabetic Retinopathy	30		Steroid Refractory Phenotype	49		
4.2	Inflammatory Processes Mediate		5.5	Immune Mechanisms of			
	Diabetic Macula Edema	31		Steroid Resistance	50		
4.2.1	Diabetic Vascular Leakage		5.6	Future Directions: Novel Strategies			
	is Mediated by Inflammation	31		to Optimise Glucocorticoid			
4.2.2	Diabetic Vascular Leakage			Treatment	52		
	Can Be Inhibited		5.6.1	Targeting Steroid Refractory			
	by Anti-inflammatory Agents	31		Cd4 ⁺ Cd25 ^{int} Cells	52		
4.3	Inflammatory Aspects of Retinal		5.6.2	Other Approaches	52		
	Vascular Remodeling and Growth	32	0.0.2	References	52		
4.3.1	Leukocytes Mediate Retinal				-		
	Vascular Remodeling During		Chapt	Chapter 6			
	Development and Vaso-Obliteration			Multiple Sclerosis and Uveitis			
	in Disease	32					
4.3.2	Effects of VEGF on Ocular	-	Graen	ie j. wimams			
	Neovascularisation and Vascular		6.1	Introduction	55		
	Permeability	33	6.2	Association Between Multiple			
4.4	Clinical Application of			Sclerosis and Uveitis	55		
	the Inflammatory Concept		6.3	Clinical Findings in			
	in Diabetic Retinopathy	34	0.0	MS-Associated Uveitis	56		
4.4.1	Nonsteroidal Anti-inflammatory	51	6.4	Histopathological Findings	57		
1. 1. 1	Drugs	34	6.5	Experimental Models	58		
4.4.2	Corticosteroids	34	6.6	Treatment	58		
4.4.3	Antiangiogenic Treatment	35	0.0	References	58		
4.4.3.1	Phase 2 Trial: Intravitreous	55		neierences	50		
7.7.5.1	Pegaptanib as a Treatment		Chan	7 · · · · · · · · · · · · · · · · · · ·			
	for DME	35	Chapter 7				
4.4.3.2	Clinical Experience with	رر	5 Inflammation in Age-Related Macular Degeneration: What is the Evidence?				
7.7.3.2	Bevacizumab in Diabetic		_				
		<i>37</i>	Hepin	g Xu, John V. Forrester			
4.4.3.3	RetinopathyRanibizumab in Diabetic	3/	7.1	Introduction	61		
4.4.3.3		20		Evidence from Clinical Studies	62		
	Macula Edema	38 30	7.2 7.2.1		62		

Contents XI

7.2.2	Epidemiological Evidence for	<i>(</i> 2	8.9	Retinal Transplantations	82
7221	Inflammatory Markers in AMD	62		References	82
7.2.2.1	C-Reactive Protein (CRP)	62			
7.2.2.2	IL-6.	62			
7.2.2.3	Tumor Necrosis Factor- α (TNF- α)	63		of Retinal Vascular	
7.2.2.4	Intercellular Adhesion Molecule		Involvement in the Diagnosis of Retinal Vasculitis		
7225	(ICAM)-1				
7.2.2.5	Circulating White Blood Cell (WBC) Count	63	Miles R. S	Stanford, Rashmi Mathew	
7.2.2.6	Retinal Autoantibodies	63	9.1	Introduction	87
7.2.2.7	Other Markers	63	9.2	Pathology of Retinal Vasculitis	88
7.2.3	Inflammatory Components	05	9.2.1	General Pathology of Retinal	
7.2.3	in Drusen	64		Vessels	88
7.2.4	Evidence from Clinical	0 1	9.2.2	Pathology of Retinal Vessels	
,	Anti-inflammatory Treatment			in Specific Diseases	88
	Studies	64	9.2.2.1	Behçet's Disease	88
7.3	Evidence from Experimental	-	9.2.2.2	Tuberculosis	88
	Studies	64	9.2.2.3	Sarcoidosis	89
7.3.1	Myeloid Cells in the Pathogenesis	-	9.2.2.4	Multiple Sclerosis	89
	of AMD	64	9.2.2.5	Idiopathic Isolated Retinal Vasculitis	89
7.3.1.1	Choroidal Monocytes		9.2.2.6	Acute Retinal Necrosis	89
	in the Pathogenesis of AMD	64	9.2.2.7	Sympathetic Ophthalmia	89
7.3.1.2	Retinal Microglia in		9.3	Clinical Features of Retinal	
	the Pathogenesis of AMD	65		Vasculitis	90
7.3.2	Complement Activation		9.3.1	Primary, Idiopathic, Isolated RV	90
	in Age-Related Macular		9.3.2	Systemic Disease and RV	92
	Degeneration	67	9.3.2.1	Behçet's Disease	92
7.4	Conclusion	68	9.3.2.2	Eales Disease	92
	References	68	9.3.2.3	Tuberculosis	93
			9.3.2.4	Sarcoidosis	93
Chapte	r 8		9.3.2.5	Multiple Sclerosis	93
	elated Macular Degeneration:		9.3.3	Retinal Vasculitis Associated	
	ological Factors in the Pathogenesis			with Infection	94
and Th	erapeutic Consequences		9.3.3.1	Viral Retinitis	94
Aize Kijlstra, Ellen C. La Heij, Fleur Goezinne,			9.3.3.2	Syphilis	95
Fred He	endrikse			References	95
8.1	Introduction	<i>73</i>	Chapter	10	
8.2	Inflammatory Cells in the Choroid		Masquerade Syndromes		
0.2	and Retina in AMD	74	-		
8.3	Infectious Pathogens and AMD	75	Shouvik	Saha, Elizabeth M. Graham	
8.4	Role of Autoimmunity in AMD	76	10.1	Introduction	97
8.5	Drusen as Triggers of Complement		10.2	Lymphoproliferative	
	Activation in AMD	76		Malignancies	97
8.6	Genetic Factors Related		10.2.1	Primary Intraocular Lymphoma	97
	to Inflammation and AMD	78	10.2.1.1	Introduction	97
8.7	Anti-inflammatory Effects		10.2.1.2	Epidemiology	98
	of Nutritional Factors	79	10.2.1.3	Clinical Features	98
8.8	Anti-inflammatory Drugs		10.2.1.4	Fluorescein Angiography	99
	and AMD	80	10.2.1.5	Ultrasonography	100
8.8.1	Angiostatic Steroids	80	10.2.2	Special Investigations	100
8.8.2	Antiangiogenic Therapy		10.2.2.1	Neuroradiology	100
	in AMD	81	10.2.2.2	Cerebrospinal Fluid Analysis	101
8.8.3	Immunotherapy for AMD	81	10.2.3	Tissue Biopsy	101

10.2.3.1	Vitreous Sampling	101	10.2.9	Leukaemias	107
10.2.3.2	Other Tissue Sampling Techniques	101	10.2.10	Paraproteinaemias	107
10.2.4	Tissue Analysis Techniques	101	10.3	Nonlymphoproliferative	
10.2.4.1	Cytology	101		Malignancies	108
10.2.4.2	Immunohistochemistry	102	10.3.1	Uveal Melanoma	108
10.2.4.3	Cytokines	103	10.3.1.1	Clinical Features	108
10.2.4.4	Molecular Analysis	103	10.3.1.2	Diagnosis	108
10.2.5	Treatment	103	10.3.1.3	Management	108
10.2.5.1	Radiation Therapy	103	10.3.2	Retinoblastoma	109
10.2.5.2	Chemotherapy	103	10.3.2.1	Clinical Features	109
10.2.5.3	Combination Chemotherapy		10.3.2.2	Diagnosis	109
	and Radiotherapy	104	10.3.2.3	Management	109
10.2.6	Prognosis	104	10.3.3	Ocular Metastases	110
10.2.7	Primary Uveal Lymphoma	104	10.3.3.1	Clinical Features	110
10.2.8	Secondary Intraocular		10.3.3.2	Diagnosis	110
	Lymphomas	105	10.3.4	Juvenile Xanthogranuloma	111
10.2.8.1	Diffuse Large B-Cell		10.3.4.1	Clinical Features	111
	Lymphoma	106	10.3.4.2	Diagnosis	111
10.2.8.2	Intravascular B-Cell		10.3.4.3	Management	111
	Lymphoma (Malignant			References	112
	Angioendotheliomatosis)	106			
10.2.8.3	T or T/Nk-Cell Lymphomas	106	Index		117

Contributors

Daniel Böhringer

University of Freiburg Department of Opthalmology Killianstraße 5 79106 Freiburg, Germany

John H. Chang

Laboratory of Ocular Immunology Inflammatory Diseases Research Unit School of Medical Sciences University of New South Wales Sydney, Australia and Department of Ophthalmology St Vincent's Hospital Sydney, Australia

S. John Curnow

Institute of Biomedical Research Division of Immunity and Infection Medical School The University of Birmingham Birmingham B15 2TT, UK

A.K.O. Denniston

Institute of Biomedical Research
MRC Centre for Immune Regulation
Division of Immunity and Infection
Medical School, The University of Birmingham
Birmingham B15 2TT, UK;
Academic Unit of Ophthalmology
Division of Immunity and Infection
Birmingham and Midland Eye Centre
University of Birmingham
City Hospital NHS Trust
Birmingham B18 7QU, UK

Andrew D. Dick

Academic Unit of Ophthalmology University of Bristol and Bristol Eye Hospital Lower Maudlin Street Bristol BS1 2LX, UK

John V. Forrester

Department of Ophthalmology Institute of Medical Sciences, Foresterhill University of Aberdeen Aberdeen, AB 25 2ZD Scotland, UK

F. Goezinne

Eye Research Institute Maastricht Department of Ophthalmology University Hospital Maastricht P. Debyelaan 25, 6202 AZ, Maastricht The Netherlands

Elizabeth Graham

Department of Ophthalmology Guy's & St. Thomas' NHS Trust London, UK

F. Hendrikse

Eye Research Institute Maastricht Department of Ophthalmology University Hospital Maastricht P. Debyelaan 25, 6202 AZ, Maastricht The Netherlands

Antonia M. Joussen

Department of Ophthalmology University of Duesseldorf Moorenstrabe 5, 40225 Duesseldorf Germany

A. Kijlstra

Eye Research Institute Maastricht Department of Ophthalmology University Hospital Maastricht P. Debyelaan 25, 6202 AZ, Maastricht The Netherlands

E.C. La Heij

Eye Research Institute Maastricht Department of Ophthalmology University Hospital Maastricht P. Debyelaan 25, 6202 AZ, Maastricht The Netherlands

Richard W.J. Lee

Academic Unit of Ophthalmology University of Bristol and Bristol Eye Hospital Lower Maudlin Street Bristol BS1 2LX, UK

Rashmi Mathew

Department of Ophthalmology Medical Eye Unit St Thomas' Hospital London SE1 7EH, UK

Peter J. McCluskey

Laboratory of Ocular Immunology
Inflammatory Diseases Research Unit
School of Medical Sciences
University of New South Wales
Sydney, Australia
and
Department of Ophthalmology
St Vincent's Hospital
Sydney, Australia
and
Department of Ophthalmology
Royal Prince Alfred Hospital
Sydney, Australia

Ben J.E. Raveney

Academic Unit of Ophthalmology University of Bristol and Bristol Eye Hospital Lower Maudlin Street Bristol BS1 2LX, UK

T. Reinhard

University of Freiburg Department of Opthalmology Killianstraße 5 79106 Freiburg, Germany

Shouvik Saha

Department of Ophthalmology Guy's & St. Thomas' NHS Trust London, UK

Lauren P. Schewitz

Academic Unit of Ophthalmology University of Bristol and Bristol Eye Hospital Lower Maudlin Street Bristol BS1 2LX, UK

Miles Stanford

St Thomas' Hospital Department of Clinical Ophthalmology Medical Eye Unit London SE1 7EH, UK

Denis Wakefield

Laboratory of Ocular Immunology Inflammatory Diseases Research Unit School of Medical Sciences University of New South Wales Sydney, Australia and Department of Ophthalmology St Vincent's Hospital Sydney, Australia

Graeme J. Williams

Diabetes Retinal Screening Service David Anderson Building Foresterhill Road Aberdeen, AB25 2ZP UK

Heping Xu

Department of Ophthalmology Inflammation and Immunity Theme School of Medicine Institute of Medical Sciences (IMS) University of Aberdeen, Foresterhill Aberdeen, AB25 2ZD Scotland, UK